Chemomab Therapeutics (CMMB) announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis, PSC, were published in the current issue of the American Journal of Gastroenterology. The study showed that nebokitug was generally safe and well tolerated in patients with PSC for up to 48 weeks of treatment. Patients treated with nebokitug had numerical improvements in a range of biomarkers for inflammation and fibrosis, particularly at the 20 mg/kg dose and in the pre-specified subgroup of patients with moderate/advanced fibrosis. The authors conclude that these promising data support further evaluation of nebokitug for the treatment of PSC in a Phase 3 clinical trial.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMMB:
- Chemomab Therapeutics Advances PSC Treatment with Phase 3 Trial
- Chemomab Therapeutics Advances Nebokitug Phase 3 Trial with Regulatory Support
- Chemomab Therapeutics reports Q3 EPS (0.4c) vs (1c) last year
- Chemomab announces presentations at AASLD 2025 on nebokitug data
- CMMB Earnings this Week: How Will it Perform?